The 8th World Congress on Controversies in Multiple Myeloma (COMy) took place from May 12 - 15 2022 in Paris, France, and virtually. This meeting brought world experts together to discuss the latest controversies in multiple myeloma.
View all videos

COMy 2022

COMy 2022
12–15 May 2022 | Paris, France / Online

At #EHA2022, we spoke with @NGhoshMD on mechanisms of resistance to immunotherapy in NHL.

Watch his interview here:

🎥: http://ow.ly/xasW50K4epi

@EHA_Hematology #HemOnc #LymSM #ImmunoOnc

Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Just published in ⁦@BloodJournal⁩ - excellent analysis highlighting the value of quadruplet inductions prior to ASCT ⁦@TheIACH⁩ https://ashpublications.org/blood/article/140/6/594/485281/Daratumumab-in-first-line-therapy-is-cost

If you missed out on #iwMDS2022, don't worry!

You can catch up with all expert-led roundtable discussions with our latest session🤩

➡️http://ow.ly/NMTU50K4ee8⬅️

#MDSsm #MyelodysplasticSyndromes #LeuSM #AMLsm #HemOnc

📢 Two weeks until #IMS2022! 📢

🚨 Don’t forget to set a reminder on August 25-27 to hear the latest updates in the field of #MultipleMyeloma from leading #HemOnc experts!

@VJHemOnc @Myeloma_Society #MMSM #Myeloma #Amyloidosis #ImmunoOnc

Jahanzaib Khwaja (@uclh) discusses unmet needs in AL amyloidosis and treatment options for patients with R/R disease:

🎥: http://ow.ly/OJJi50K4cVc

@EHA_Hematology #HemOnc #RareDiseases #Amyloidosis #ImmunoOnc

Load More...

COMy 2022

COMy 2022
12–15 May 2022 | Paris, France / Online
The 8th World Congress on Controversies in Multiple Myeloma (COMy) took place from May 12 - 15 2022 in Paris, France, and virtually. This meeting brought world experts together to discuss the latest controversies in multiple myeloma.
View all videos

At #EHA2022, we spoke with @NGhoshMD on mechanisms of resistance to immunotherapy in NHL.

Watch his interview here:

🎥: http://ow.ly/xasW50K4epi

@EHA_Hematology #HemOnc #LymSM #ImmunoOnc

Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Just published in ⁦@BloodJournal⁩ - excellent analysis highlighting the value of quadruplet inductions prior to ASCT ⁦@TheIACH⁩ https://ashpublications.org/blood/article/140/6/594/485281/Daratumumab-in-first-line-therapy-is-cost

If you missed out on #iwMDS2022, don't worry!

You can catch up with all expert-led roundtable discussions with our latest session🤩

➡️http://ow.ly/NMTU50K4ee8⬅️

#MDSsm #MyelodysplasticSyndromes #LeuSM #AMLsm #HemOnc

📢 Two weeks until #IMS2022! 📢

🚨 Don’t forget to set a reminder on August 25-27 to hear the latest updates in the field of #MultipleMyeloma from leading #HemOnc experts!

@VJHemOnc @Myeloma_Society #MMSM #Myeloma #Amyloidosis #ImmunoOnc

Jahanzaib Khwaja (@uclh) discusses unmet needs in AL amyloidosis and treatment options for patients with R/R disease:

🎥: http://ow.ly/OJJi50K4cVc

@EHA_Hematology #HemOnc #RareDiseases #Amyloidosis #ImmunoOnc

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter